<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03068494</url>
  </required_header>
  <id_info>
    <org_study_id>2016-12-136</org_study_id>
    <nct_id>NCT03068494</nct_id>
  </id_info>
  <brief_title>Korean Coronary Bifurcation Stenting (COBIS) Registry III</brief_title>
  <acronym>COBIS III</acronym>
  <official_title>Multicenter, Retrospective Korean Coronary Bifurcation Stenting (COBIS) Registry III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COBIS III registry is a multi-center, real-world registry of 2nd generation drug-eluting
      stenting in coronary bifurcation lesions in South Korea. From 31 major coronary intervention
      centers in Korea, a total of 3,000 patients (anticipated) will be enrolled in this database
      between January 2010 and December 2014.

      The aim of the study was to investigate long-term clinical results and predictors of adverse
      outcomes after percutaneous coronary intervention with 2nd generation drug-eluting stents for
      coronary bifurcation lesions in South Korea.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>3 years</time_frame>
    <description>composite of cardiac death, myocardial infarction, or target lesion revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>3 years</time_frame>
    <description>All deaths were considered cardiac cause unless obvious non-cardiac causes could be identified</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>3 years</time_frame>
    <description>an elevation of creatine kinase-myocardial band or troponin level greater than the upper limit of normal with concomitant ischemic symptoms or electrocardiography findings indicative of ischemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>3 years</time_frame>
    <description>repeat PCI of the lesion within 5 mm of the inserted stent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>3 years</time_frame>
    <description>the Academic Research Consortium as definite, probable, or possible</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Coronary Bifurcation Lesion</condition>
  <arm_group>
    <arm_group_label>Coronary Bifurcation Lesion</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with coronary bifurcation lesion treated with 2nd generation drug-eluting stents
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;=19 years

          -  Any type of de novo bifurcation lesion in major epicardial artery: unprotected left
             main coronary bifurcation lesion, LAD - diagonal, LCX-OM, distal RCA bifurcation.
             (Excluding RCA-RV branch bifurcation, branch bifurcation)

          -  Side branch or LCX reference diameter &gt;= 2.3 mm and at least stentable with 2.5 mm
             stent

          -  Treated with drug-eluting stent during the period of 2010. 1 ~ 2014. 12

        Exclusion Criteria:

          -  Protected left main disease previous CABG for LAD or LCX territory

          -  Cardiogenic Shock

          -  History of CPR in the same hospitalization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeon-Cheol Gwon, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young Bin Song, Professor</last_name>
    <phone>8221099330108</phone>
    <email>youngbin.song@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyoen-Cheol Gwon, PhD</last_name>
      <phone>82-2-3410-3418</phone>
      <email>hcgwon@skku.edu</email>
    </contact>
    <investigator>
      <last_name>Hyoen-Cheol Gwon, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Hyeon-Cheol Gwon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Coronary Bifurcation Lesion</keyword>
  <keyword>2nd generation drug-eluting stent</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

